AR071852A1 - Formulacion farmaceutica de un anticuerpo frente a ox40l - Google Patents
Formulacion farmaceutica de un anticuerpo frente a ox40lInfo
- Publication number
- AR071852A1 AR071852A1 ARP090101807A ARP090101807A AR071852A1 AR 071852 A1 AR071852 A1 AR 071852A1 AR P090101807 A ARP090101807 A AR P090101807A AR P090101807 A ARP090101807 A AR P090101807A AR 071852 A1 AR071852 A1 AR 071852A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- ox40l
- pharmaceutical formulation
- antibody against
- polysorbate
- Prior art date
Links
- 102000004473 OX40 Ligand Human genes 0.000 title abstract 5
- 108010042215 OX40 Ligand Proteins 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 2
- 229940068977 polysorbate 20 Drugs 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 239000012929 tonicity agent Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una formulacion farmaceutica que comprende: de 1 a 200 mg/mL de un anticuerpo; de 1 a 100 mM de un tampon; de 0,001 al 1% de un surfactante; (a) de 10 a 500 mM de un estabilizador; o (b) de 10 a 500 mM de un estabilizador y de 5 a 500 mM de un agente de tonicidad; o (c) de 5 a 500 mM de un agente de tonicidad; a un pH en el rango de entre 4,0 y 7,0, en el que el anticuerpo es un anticuerpo frente a OX40L. Reivindicacion 2: La formulacion de acuerdo con la reivindicacion 1 en la que el anticuerpo se caracteriza en que dicho anticuerpo se une OX40L, contiene una parte Fc de origen humano y no se une al factor Clq del complemento. Reivindicacion 9: La formulacion l¡quida de la reivindicacion 1 que comprende: huMAb OX40L 1 a 50 mg/mL, L-histidina HCl 20 mM, trehalosa 240 mM, polisorbato 20 al 0,02%, a pH 6,0, o huMAb OX40L 1 a 50 mg/mL, tampon citrato 20 mM, sacarosa 240 mM, arginina 20 mM, polisorbato 20 al 0,02%, a pH 5,5. Reivindicacion 11: El uso de una formulacion de acuerdo con cualquiera de las reivindicaciones 1 a 10 para la preparacion de un medicamento util para tratar un trastorno inflamatorio, por ejemplo asma, artritis reumatoide o alergia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156579 | 2008-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071852A1 true AR071852A1 (es) | 2010-07-21 |
Family
ID=40898050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101807A AR071852A1 (es) | 2008-05-20 | 2009-05-20 | Formulacion farmaceutica de un anticuerpo frente a ox40l |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100098712A1 (es) |
| AR (1) | AR071852A1 (es) |
| PE (1) | PE20091852A1 (es) |
| TW (1) | TW201000128A (es) |
| WO (1) | WO2009141239A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| LT2704742T (lt) | 2011-05-02 | 2017-10-25 | Millennium Pharmaceuticals, Inc. | Anti-alfa4beta7 antikūno kompozicija |
| CN107880123A (zh) | 2011-10-28 | 2018-04-06 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| FI3265123T3 (fi) * | 2015-03-03 | 2023-01-31 | Vasta-aineita, käyttöjä & menetelmiä | |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| JP7198752B2 (ja) | 2016-08-09 | 2023-01-04 | カイマブ・リミテッド | 抗ｉｃｏｓ抗体 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| EP4559485A3 (en) * | 2018-07-19 | 2025-08-06 | Ichnos Sciences S.A. | Liquid antibody formulation |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CA3201564A1 (en) | 2020-12-09 | 2022-06-16 | Jung Min Yoo | Anti-ox40l antibody, anti-ox40l/anti-tnfalpha bispecific antibody, and uses thereof |
| WO2024213774A1 (en) * | 2023-04-14 | 2024-10-17 | Kymab Limited | Pharmaceutical formulations containing anti-ox40l antibodies |
| AU2024261144A1 (en) * | 2023-04-28 | 2025-09-04 | Apogee Therapeutics, Inc. | Antibodies that bind ox40l and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2007133290A2 (en) * | 2005-12-16 | 2007-11-22 | Genentech, Inc. | Anti-ox40l antibodies and methods using same |
-
2009
- 2009-05-11 WO PCT/EP2009/055647 patent/WO2009141239A1/en not_active Ceased
- 2009-05-18 PE PE2009000693A patent/PE20091852A1/es not_active Application Discontinuation
- 2009-05-19 TW TW098116588A patent/TW201000128A/zh unknown
- 2009-05-20 AR ARP090101807A patent/AR071852A1/es unknown
- 2009-05-20 US US12/454,598 patent/US20100098712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201000128A (en) | 2010-01-01 |
| PE20091852A1 (es) | 2009-12-31 |
| WO2009141239A1 (en) | 2009-11-26 |
| US20100098712A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071852A1 (es) | Formulacion farmaceutica de un anticuerpo frente a ox40l | |
| EA201792552A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| BR112014019667A2 (pt) | formulação de anticorpo abeta | |
| ECSP088903A (es) | Composiciones farmacéuticas de anticuerpo antagonista anti-cd40 | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| BR112017008660A2 (pt) | formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf | |
| MX362382B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| PE20181790A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| CO6680698A2 (es) | Formulación de premezcla de dexmedetomidina | |
| AR095396A1 (es) | Formulaciones de anticuerpo | |
| PE20081477A1 (es) | Formulacion liofilizada mab abeta | |
| UA122478C2 (uk) | Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1 | |
| AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
| CO7111300A2 (es) | Formulación de anticuerpos | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| EA201200204A1 (ru) | Содержащая антитело к her2 композиция для подкожного введения | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| BR112012021638A2 (pt) | composição livre de conservantes estéril ótica farmacêutica na forma de uma solução aquosa clara. | |
| CL2021001587A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |